Study title:
van den Berg H et al, Favorable outcome after 1-year treatment of childhood T-cell lymphoma/T-cell, acute lymphoblastic leukemia, Med Pediatr Oncol. 1998 Jan;30(1):46-51. Erratum in: Med Pediatr Oncol 1998 May;30(5):318van den Berg H et al, Favorable outcome after 1-year treatment of childhood T-cell lymphoma/T-cell, acute lymphoblastic leukemia, Med Pediatr Oncol. 1998 Jan;30(1):46-51. Erratum in: Med Pediatr Oncol 1998 May;30(5):318
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: BLEOMYCIN |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
Y
|